Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Aug 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2010 Apr 2;8(8):682–687.e1. doi: 10.1016/j.cgh.2010.03.022

Table 4.

Medication usage during 1^st year of disease for all patients.

	Early-onset N (%)	Late-onset N (%)	P value
5-ASA compounds
Oral	137 (88.4)	135 (96.4)	0.01*
Rectal	53 (34.2)	56 (40.0)	0.30
Steroids
Oral	98 (63.2)	94 (67.8)	0.48
Rectal	12 (7.7)	19 (13.6)	0.10
IV	21 (13.5)	21 (15.0)	0.72
Immunomodulators	40 (25.8)	41 (29.3)	0.50
Infliximab	7 (4.5)	8 (5.7)	0.64